NCT05823883

This Study is to Compare and Evaluate the Safety and Pharmacokinetic Characteristics (PK) After Administration of DW6014 and Each Component in Healthy Adult Volunteers in Fed Condition.

A Phase 1 Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic Characteristics After Administration of Fixed Dose Combination of DW6014 and Loose Combination of Each Component in Healthy Adult Volunteers in Fed Condition

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Dong Wha Pharmaceutical Co. Ltd. · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Accepted

Summary

This study is to compare and evaluate the safety and pharmacokinetic characteristics (PK) after administration of DW6014 and each component in healthy adult volunteers in fed condition.

Detailed description

This is a Phase 1, randomized, open-label, Oral, Single-dose, two-way crossover study in healthy subjects.

Conditions

• DW6014

Interventions

Type	Name	Description
DRUG	DW6014	Drug: DW6014 Single oral administration of DW6014 in fed condition Drug: Empagliflozin and Metformin Combination oral administration of Empagliflozin and Metformin in fed condition

Timeline

• Start date: 2023-06-01
• Primary completion: 2023-07-01
• Completion: 2023-08-01
• First posted: 2023-04-21
• Last updated: 2023-05-26

Locations

1 site across 1 country: South Korea